Skip to main content
. Author manuscript; available in PMC: 2014 Dec 2.
Published in final edited form as: Mol Pharm. 2013 Oct 25;10(12):4534–4545. doi: 10.1021/mp400355q

Figure 3.

Figure 3

Optimization of the nanocomplex formulation. (A) Gel retardation assay of the SSC complexes at different molar ratios of siRNA:streptavidin:cholesterol. (B) Gel retardation assay of the SSCP nanocomplexes at different N/P ratios. The SSC complex with the molar ratio 2:1:2 (siRNA:streptavidin:cholesterol) was condensed with protamine at different N/P ratios and incubated for 30min. (C &D) Disulfide bond cleavage study. Heparin is added to dissociate cleaved siRNA from the nanocomplex prior to gel electrophoresis.